The ability of Electronic
Brachytherapy to accurately and consistently deliver localized,
non-radioactive radiation treatment directly to cancer sites is the focus
of a symposium and multiple research papers accepted for presentation at
the 50th American Association of Physicists in Medicine Meeting, July 27 -
31 in Houston. According to Xoft, Inc., developer of the Axxent(R)
Electronic Brachytherapy System, positive clinical results from initial
breast cancer treatment experience has generated significant momentum for
adoption of Electronic Brachytherapy (eBx). It has also spurred much
research validating eBx use in additional applications, including the
treatment of endometrial and endocavitary cancers.
In conjunction with the AAPM Meeting, Xoft is hosting a luncheon
symposium, titled "Clinical and Regulatory Considerations for Electronic
Brachytherapy." Featuring a panel of leading physicists and radiation
biology experts, the panel discussion will focus on breast cancer treatment
experience to date, the impact of broader implementation of Electronic
Brachytherapy on physicist workflow, dosimetry and treatment planning, and
the regulation and control of the use of X-ray radiation sources.
"As one of the early clinical sites to treat breast cancer patients
with Electronic Brachytherapy, we see this as a rapidly emerging treatment
technique that not only competes well with existing HDR options, but has a
number of distinct benefits," said Salahuddin Ahmad, PhD, DABR, professor
and director of Medical Physics, Department of Radiation Oncology,
University of Oklahoma Health Sciences Center. "This includes supporting a
shorter, five day treatment regimen without the use of a radioactive
isotope, giving treatment centers the flexibility to perform treatment in
minimally shielded rooms and offering patients a better experience since
they no longer have to be isolated in a shielded room.
"We have been encouraged by our experience with the treatment of breast
cancer and look forward to offering this technique as it expands to new
applications, such as the treatment of endometrial cancer," Dr. Ahmad
added.
Separately, in the presented paper, "An Enabling Technology for
Creating Sculpted Brachytherapy Dose Patterns with the Xoft Axxent(R)
System," one of more than 10 studies about Electronic Brachytherapy
accepted for presentation, Xoft scientists studied the ability to partially
attenuate X-rays from the Axxent system over controlled spatial areas,
while minimizing changes to depth-dose characteristics. This would be the
basis of an enabling technology to sculpt brachytherapy dose patterns to
spare nearby critical structures, such as skin in breast brachytherapy
treatments or bladder and rectum in gynecological brachytherapy. Results
demonstrated that it is possible to create predictable, directed shadows in
dose around the 50 kVp X-ray source. In a simulated breast treatment plan,
using a simple model of the attenuation, isodose lines were shifted by
several mm.
A series of studies compared the dose delivered by the Electronic
Brachytherapy system in endocavitary applications to the dose predicted
through treatment planning. In the study, "Dosimetry of an X-ray
Endocavitary Proctoscope Adapted for use with the Axxent(R) Electronic
Brachytherapy System," researchers from Washington University in St Louis
and Xoft analyzed the dose rate and uniformity at the aperture of an
Electro-Surgical Instrument (ESI) Proctoscope when used with an Axxent
X-ray Source. Measurements of dose rate and uniformity at the aperture of a
24 mm diameter ESI proctoscope indicate that the Axxent X-ray source may be
a suitable alternative to the Philips RT-50 Endocavitary Unit for treatment
of anal-rectal lesions.
About Axxent Electronic Brachytherapy
The Axxent(R) Electronic Brachytherapy System has been developed to
address a variety of oncological and non-oncological indications. The
proprietary Axxent treatment platform is cleared for use in the treatment
of cancers or conditions where radiation therapy is indicated. Specific
applicators have been cleared for treatment of early stage breast cancer
and endometrial and rectal indications. Designed to deliver electronic,
X-ray- based radiation treatment, the Axxent System can be used in
virtually any clinical setting under the supervision of a radiation
oncologist. It is designed to deliver non-radioactive therapy directly to
cancer sites with minimal radiation exposure to surrounding healthy tissue.
Eliminating the need for heavily shielded environments, it gives radiation
oncologists the flexibility to deliver therapy in a broader range of
clinical settings without the complex handling and resource logistics
necessary when performing brachytherapy using radioactive isotopes. As a
result, tens of thousands of patients annually will have greater access to
therapy that is delivered more easily and conveniently.
About Xoft, Inc.
Founded in 1998, Xoft develops leading-edge technologies for the
practice of radiation oncology through Electronic Brachytherapy, which
utilizes proprietary miniaturized X-ray tube technology. The Axxent(R)
Electronic Brachytherapy System, Xoft's first treatment system, is
currently being used in Accelerated Partial Breast Irradiation (APBI) for
the treatment of early- stage breast cancer and in the treatment of
endometrial cancer. For more information, visit xoftinc
Axxent and FlexiShield are trademarks of Xoft, Inc.
Xoft, Inc.
xoftinc
Комментариев нет:
Отправить комментарий